companydata.dkSYNACT PHARMA ApS: Financial statements 2023
CVR: 34459975
SYNACT PHARMA ApS (CVR 34459975) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -63,448,353 and a net result of DKK -65,408,926 compared with DKK -49,780,297 the year before. Equity amounted to DKK 15,585,962. The solvency ratio was 58.2%. The company had 3 employees in the financial year.
- Gross Profit
- -63,448,353 kr.
- Profit/Loss
- -65,408,926 kr.
- Equity
- 15,585,962 kr.
- Total Assets
- 26,784,891 kr.
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -63.4 mio. | -65.4 mio. | 15.6 mio. | 3 |
| 2022 | - | -47 mio. | -49.8 mio. | 34 mio. | 3 |
| 2021 | - | -43.4 mio. | -41.2 mio. | 6.6 mio. | 2 |
| 2020 | - | -16.7 mio. | -14 mio. | 11.4 mio. | - |
| 2019 | - | -11.5 mio. | -9.8 mio. | -21.8 mio. | - |
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of June 15, 2023, Björn Uno Bernhard Westberg is registered as director of SYNACT PHARMA ApS.
As of June 15, 2023, Patrik Renblad has stepped down as director of SYNACT PHARMA ApS.
SYNACT PHARMA ApS has published its annual report for 2022. Gross profit came to DKK -46,951,479, and the net result was DKK -49,780,297.
As of May 25, 2023, Torbjørn Bjerke is registered as adm. dir. of SYNACT PHARMA ApS.
As of May 25, 2023, Thomas Boesen is registered as director of SYNACT PHARMA ApS.
As of May 25, 2023, Jeppe Øvli Øvlesen has stepped down as adm. dir. of SYNACT PHARMA ApS.
About SYNACT PHARMA ApS
SYNACT PHARMA ApS is a Danish company of the type Anpartsselskab based in Holte, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named SYNACTION PHARMA ApS. The management consists of Jeppe Øvli Øvlesen, Thomas Boesen and Ann Kristin Brøgger Led. The company is owned by SynAct Pharma AB. In 2025, the company reported a gross profit of DKK -53,194,923 and a net result of DKK -59,812,937 compared with DKK -30,477,376 the year before. Equity amounted to DKK 20,295,649.